Supercomputer simulations have revealed how changes in the shape of the HIV-1 capsid protein may help the virus squeeze its ...

Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But ...

An HIV drug was named “2024 Breakthrough of the Year” by Science Magazine. Biochemistry research from the University of Utah ...

A multi-national, multi-institutional study investigators found little natural resistance to a new HIV therapy called lenacapavir in a population of patients in Uganda.

Lenacapavir, however, is the first drug to disrupt the protective capsid layer surrounding HIV's genetic material (RNA), blocking the virus's ability to reproduce and be transmitted from person to ...

Inset: Interior view a HIV-1 virus showing the capsid (yellow) that surrounds the RNA and enzymes necessary for replication. A multi-national, multi-institutional study led by Weill Cornell ...

Lenacapavir is an HIV capsid inhibitor with a long half-life in the body, meaning it can be administered once every six months. Phase 3 studies showed that it dramatically reduced HIV acquisition in ...

Lenacapavir, however, is the first drug to disrupt the protective capsid layer surrounding HIV’s genetic material (RNA), blocking the virus’s ability to reproduce and be transmitted from person to ...

a twice-yearly injectable HIV-1 capsid inhibitor as a PrEP medication. Dietmar Berger, MD, PhD, chief medical officer for Gilead Sciences, said in a written statement that this approval brings the ...

Organoids were cultured from healthy donor iPSC sources and differentiated using the human iPSC-derived Cerebral Organoid ...